Trials / Unknown
UnknownNCT02525237
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Qingdao Municipal Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity |
| DRUG | S-1 | S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-08-01
- Completion
- 2017-08-01
- First posted
- 2015-08-17
- Last updated
- 2015-08-17
Source: ClinicalTrials.gov record NCT02525237. Inclusion in this directory is not an endorsement.